CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Wilson I Gonsalves
Mayo Clinic Cancer Center LAO
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Yale University
New Haven, Connecticut, United States
- Moffitt Cancer Center
Tampa, Florida, United States
- Mayo Clinic in Rochester
Rochester, Minnesota, United States
- Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States
- Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 8 Jul 2019
- Primary completion
- 11 Sept 2026
- Completion
- 11 Sept 2026
- Last update posted
- 27 May 2026
- Registered enrollment
- 36
- Registry id
- NCT03798678
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.